| Today’s Big NewsApr 18, 2024 |
| By Nick Paul Taylor The backing singer in AbbVie’s $8.7 billion takeover of Cerevel Therapeutics is having its moment in the spotlight. |
|
|
|
By Fraiser Kansteiner Novo Nordisk is receiving pushback from a trio of lawmakers on its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year. |
By Conor Hale 23andMe’s co-founder and CEO Anne Wojcicki has put in motion a plan to take the company private after the stock value of the DNA testing provider has collapsed by more than 97% since its multibillion-dollar market debut just three years ago. |
By Annalee Armstrong A thinner, leaner biotech forest arrived at the American Association for Cancer Research conference in San Diego ready to showcase the budding data that has sprouted as a result of difficult decisions made during the sector’s so-called “nuclear winter.” |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Zoey Becker The FDA now expects most doses of the drugs to be in "limited availability" through the second quarter. Just a few weeks ago, the agency projected the supply strain would ease ease in April. |
By Gabrielle Masson Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. |
By Max Bayer Biopharma dealmaking continues to be one of the most encouraging signs of the industry's (partial) recovery. The number of deals in the first quarter more than doubled from the same period a year ago. |
By Conor Hale Bruker has emerged as the winner of an auction for NanoString and its spatial biology tech after the company filed for Chapter 11 bankruptcy earlier this year. |
By Andrea Park Lights, camera, Alexion! Fresh off earning FDA approval for its drug Ultomiris to treat certain adults with neuromyelitis optica spectrum disorder, AstraZeneca’s rare disease unit has put out a short film sharing several NMOSD patients’ stories—and emphasizing the overlaps between them. |
By Kevin Dunleavy After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is back to doing what it does best—developing, manufacturing and commercializing vaccines for a variety of infectious diseases with unmet needs. And its top priority is the launch of a chikungunya vaccine. |
By Gabrielle Masson Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor VX-548 in moderate-to-severe acute pain. |
Fierce podcastsDon’t miss an episode |
| | Morgan Health has been investing in multiple businesses over the past three years that have the potential to improve employer-sponsored healthcare. This week on “Podnosis,” Paige Minemyer from Fierce Healthcare interviews Morgan Health Partner Dan Hartman about the company's investment strategy and how to make a memorable pitch. |
|
|---|
|
|
|
Monday, April 29, 2024 | 12:30pm ET / 9:30am PTLearn how evolving healthcare delivery impacts product positioning for Integrated Delivery Networks. Discover key messages, stakeholders, and shifts in IDN perceptions post-COVID-19. Claim your spot.
|
|
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBookUnlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
